kaitanni cadonilimab injection 125mg(10ml)vial

Description

Indication & Scope

Cadonilimab Injection is a dual-target immunotherapeutic agent indicated for adult patients with recurrent or metastatic cervical cancer who failed prior platinum-based chemotherapy; it is also approved as first-line therapy for persistent, recurrent or metastatic cervical cancer combined with platinum-based chemotherapy.

Mechanism
As a fully humanized bispecific antibody targeting PD-1 and CTLA-4, it simultaneously blocks the binding of PD-1/CTLA-4 to their respective ligands, relieves dual immune checkpoint inhibition, activates tumor-specific T lymphocytes and enhances anti-tumor immune killing effect.
Drug class
Class 1 therapeutic biological product, recombinant human bispecific monoclonal antibody, dual immune checkpoint inhibitor for oncology.
Clinical use
Phase III clinical trials confirm its prominent survival benefit and controllable safety profile for cervical cancer patients regardless of PD-L1 expression status. Administered via intravenous infusion at 6 mg/kg every 2 weeks until disease progression or intolerable toxicity. It is the world’s first approved PD-1/CTLA-4 bispecific antibody independently developed in China.

Specification

Generic Name	Cadonilimab Injection
Brand Name	KaiTanNi®
Ingredient	Cadonilimab
Dosage Form	Solution for injection
Package	125mg(10ml)/vial
Conditions Treated	adult patients with recurrent or metastatic cervical cancer who failed prior platinum-based chemotherapy; also indicated as first-line therapy combined with platinum-based chemotherapy for persistent, recurrent or metastatic cervical cancer
Taboos	patients with hypersensitivity to cadonilimab or any excipients of this product
Place of origin	Guangdong, China
Priscription Type	Prescription drug (Rx)
Storage Conditions	Store at 2–8℃, avoid freezing and direct sunlight
Manufacturer	Kangfang Biotech Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA)
Approval number	S20220018
Date of Revision	June 29, 2022
Shelf Life	24 months

How to use ?

Recommended Dose: 6 mg/kg intravenously infused once every two weeks. Continue treatment until disease progression, intolerable toxicity or up to 24 months.

Time: Infuse over at least 30 minutes per administration; no fixed treatment cycle limit.

Interaction: Avoid concurrent use of systemic corticosteroids and immunosuppressants unless for immune-related adverse events management. Monitor patients closely when combined with chemotherapy.

Side effects: Common adverse reactions include fatigue, hypothyroidism, rash, anemia, elevated transaminases and diarrhea. Rare immune-related adverse events covering pneumonitis, colitis and endocrine disorders; severe hypersensitivity reactions occur infrequently.

Important Notice

This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support